GSK’s top scientist to quit, become CEO of anti-ageing start-up
GSK’s chief scientific officer, Hal Barron, will head up the Silicon Valley biotech Altos Labs.
By
Investment
Latest in
Investment
UK life sciences trade group calls for oral Covid-19 antiviral investment
The UK government must invest in Covid-19 antiviral treatments like it did with vaccines, said the chair of the UK…
By
Vaccibody rebrands to Nykode and bags $925m deal with Regeneron
Norwegian vaccine and immunotherapy-focused biopharma Vaccibody has rebranded to Nykode after signing a nearly $1bn deal.
By
AION Labs Q&A: driving innovation in pharma AI
AION Labs will create and invest in early-stage start-ups developing AI and computational solutions to major challenges in pharma.
By
Global warning: pharma’s role in the climate crisis
With COP26 imminent, what lessons can the pharma sector learn about its environmental impact and its response to climate change?
By
Digital survey takes litmus test on the future of AI, big data in pharma
Will the pharma industry keep up its investment in cloud computing and social media after a noticeable jump last year?
By
Billionaires are betting on anti-ageing research, but can ageing really be cured?
Amazon founder Jeff Bezos has reportedly invested in Altos Labs, a new anti-ageing start-up that hopes to prolong human life.
By
Wellcome Sanger Institute Q&A: pushing for a UK genomics revolution
The recently published Genomics Nation report has highlighted the strength and potential of the UK genomics sector.
By